In a report issued on June 24, Marie Thibault from BTIG maintained a Buy rating on Atricure (ATRC – Research Report), with a price target of $75.00. The company’s shares closed last Friday at $40.92, close to its 52-week low of $32.84.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of 6.2% and a 27.2% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.
Currently, the analyst consensus on Atricure is a Strong Buy with an average price target of $72.33, which is an 85.1% upside from current levels. In a report issued on June 14, Canaccord Genuity also maintained a Buy rating on the stock with a $72.00 price target.
Based on Atricure’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $74.58 million and GAAP net loss of $15.18 million. In comparison, last year the company earned revenue of $59.28 million and had a GAAP net loss of $16.92 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
Read More on ATRC: